![]() |
市場調查報告書
商品編碼
1514760
歐洲臨床生物標記市場 - 分析與預測(2023-2033)Europe Clinical Biomarkers Market - Analysis and Forecast, 2023-2033 |
2023年歐洲臨床生物標記市場規模達71.9億美元。
預計2023年至2033年該市場將以7.52%的複合年成長率成長,2033年達到148.4億美元。臨床生物標記是可測量的生物因素,有助於早期診斷和了解疾病的進展。這些分子生物標記為疾病研究和治療藥物開發提供了新途徑。
主要市場統計數據 | |
---|---|
預測期 | 2023-2033 |
2023年評估 | 71.9億美元 |
2033 年預測 | 148.4億美元 |
複合年成長率 | 7.52% |
在生物技術和分子生物學發展的推動下,歐洲臨床生物標記市場正在顯著擴張。臨床生物標記是可測量的生物因素。它對於了解疾病的病程、幫助早期診斷和發現新的治療標靶至關重要。預後、預測和診斷生物標記只是該領域眾多基於生物標記的測試和相關服務的一小部分。推動該產業發展的三個關鍵促進因素是:研發投資的增加、個人化治療需求的增加以及慢性病盛行率的上升。此外,歐洲法規環境正在發生變化,以促進新型生物標記技術的創建和應用。為了滿足不斷成長的需求,頂級製造商和服務供應商正致力於擴大其產品陣容並提高技術力。
本報告考察了歐洲臨床生物標記市場,概述了市場、國家趨勢以及進入市場的公司概況。
Introduction to Europe Clinical Biomarkers Market
The Europe clinical biomarkers market was valued at $7.19 billion in 2023 and is expected to reach $14.84 billion by 2033, growing at a CAGR of 7.52% between 2023 and 2033. Clinical biomarkers are biological factors that can be measured to help in early diagnosis and understanding of the course of a disease. These molecular biomarkers provide new avenues for the study of diseases and the development of therapeutics. The producers of numerous biomarker-based tests, such as prognostic, predictive, and diagnostic biomarkers, as well as associated services, are highlighted in this research.
KEY MARKET STATISTICS | |
---|---|
Forecast Period | 2023 - 2033 |
2023 Evaluation | $7.19 Billion |
2033 Forecast | $14.84 Billion |
CAGR | 7.52% |
Market Introduction
The market for clinical biomarkers in Europe is expanding significantly, propelled by developments in biotechnology and molecular biology. Clinical biomarkers are biological factors that may be measured. They are essential for comprehending the course of disease, helping with early diagnosis, and discovering novel targets for treatment. Prognostic, predictive, and diagnostic biomarkers are only a few of the many biomarker-based tests available in this sector, along with associated services. Three major drivers are driving the industry forward: increased investments in research and development, growing desire for personalized treatment, and rising prevalence of chronic diseases. Furthermore, Europe's regulatory environment is changing to facilitate the creation and application of novel biomarker technologies. To meet the increasing demand, top manufacturers and service providers are concentrating on broadening their product offerings and improving their technological prowess. This report delves into the current market dynamics, key players, and future trends shaping the European clinical biomarkers market.
Market Segmentation
Segmentation 1: by Country
How can this report add value to an organization?
Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments, at nearly 59% of the total developments in the clinical biomarkers market between January 2019 and December 2023. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.
Competitive Strategy: The Europe clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are